Should Coronary Revascularization Precede Transcatheter Aortic Valve Replacement? A Meta-Analysis of Randomized Controlled Trials

This meta-analysis of three randomized controlled trials involving 1,156 patients indicates that routine percutaneous coronary intervention (PCI) prior to transcatheter aortic valve replacement (TAVR) does not reduce mortality but significantly lowers the need for revascularization while nearly doubling the risk of bleeding, thereby supporting a selective rather than routine approach to revascularization.

The Gist

The Big Question: Fix the Pipes Before or After the Valve?

Imagine your heart is a house. The Aortic Valve is the front door, and the Coronary Arteries are the plumbing pipes that bring water (blood) to the walls of the house.

In many older patients, the front door gets stuck shut (this is called Aortic Stenosis). To fix it, doctors perform a procedure called TAVR, which is like swapping out that stuck door for a new, working one without having to break down the whole house (open-heart surgery).

However, many of these patients also have clogged pipes (Coronary Artery Disease) inside the house. The big debate among doctors has been: Should we unclog the pipes (PCI) before we swap the door, or just leave them alone and see what happens?

Some doctors thought, "Let's fix everything at once to be safe." Others thought, "Let's just fix the door; the pipes might be fine, and fixing them adds extra risk."

The Experiment: A Race of Three Trials

To settle this argument, the authors of this paper gathered data from three major, high-quality scientific races (Randomized Controlled Trials) involving 1,156 patients.

They split the runners into two groups:

1. The "Fix-It-First" Group: Got their pipes unclogged (PCI) before the new door was installed.
2. The "Wait-and-See" Group: Got the new door installed first, and only got their pipes unclogged later if they absolutely had to.

What Did They Find?

The results were a bit like a trade-off between a smoother ride and a bumpier road.

1. The "Life-Saving" Question (Mortality)

• The Result: Fixing the pipes first did not save more lives than waiting.
• The Analogy: It's like putting a new engine in a car before fixing a flat tire. You might think the car will run better, but in the end, the flat tire didn't cause the car to crash, and fixing it early didn't prevent a crash later. The death rates were the same for both groups.

2. The "Emergency Room" Question (Revascularization)

• The Result: The "Fix-It-First" group needed fewer emergency pipe repairs later on.
• The Analogy: If you unclog the pipes now, you are much less likely to have a sudden burst pipe that requires an emergency plumber later. The "Wait-and-See" group had to call the plumber more often in a panic.

3. The "Bleeding" Question (Safety)

• The Result: This was the big downside. The "Fix-It-First" group had almost double the risk of bleeding.
• The Analogy: To unclog the pipes, you have to use strong chemicals (blood thinners) and tools that can cause leaks. Because these patients are elderly and frail, these "leaks" (bleeding events) were much more common and dangerous in the group that got the extra procedure. It's like trying to fix a leaky roof while it's raining; you might stop the roof leak, but you get soaked in the process.

4. The "Heart Attack" and "Stroke" Question

• The Result: There was a slight hint that fixing the pipes early might prevent heart attacks and strokes, but the numbers weren't strong enough to say for sure. It was a "maybe," not a "definitely."

The Bottom Line

The study concludes that routinely fixing the pipes before swapping the door is not the best strategy for everyone.

• Why? Because the extra safety you get from fewer emergency repairs is canceled out by the much higher risk of dangerous bleeding.
• The New Rule: Instead of a "one-size-fits-all" approach, doctors should be like custom tailors. They should look at each patient individually.
  • If the pipes are really clogged and dangerous, fix them.
  • If the pipes are just a little dirty, maybe wait and see.

Summary in One Sentence

Fixing the heart's blood vessels before the valve replacement doesn't help patients live longer, but it does reduce the need for future emergency fixes—however, it nearly doubles the risk of dangerous bleeding, so doctors should only do it for specific patients who really need it.

Technical Summary

Technical Summary: Routine PCI Before TAVR in Patients with Concomitant CAD

Problem Statement
In patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR), the management of concomitant coronary artery disease (CAD) remains clinically uncertain. While landmark trials in stable CAD (e.g., ISCHEMIA, COURAGE) suggest elective revascularization offers no survival advantage over medical therapy, the pathophysiology of AS-induced ischemia differs due to left ventricular hypertrophy and supply-demand mismatch. Current guidelines lack a definitive recommendation on whether to perform percutaneous coronary intervention (PCI) routinely before TAVR or to defer it. This uncertainty is compounded by the procedural risks of PCI, including vascular complications and the necessity for dual antiplatelet therapy (DAPT), which significantly increases bleeding risk in the elderly TAVR population.

Methodology
The authors conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) adhering to PRISMA 2020 guidelines.

• Data Sources: PubMed, Embase, Scopus, CENTRAL, and Web of Science were searched for RCTs published between 2010 and April 2026.
• Inclusion Criteria: Adult patients (≥18 years) with severe symptomatic AS and concomitant CAD scheduled for TAVR, comparing routine PCI before TAVR (intervention) versus no PCI/conservative management (comparator).
• Included Studies: Three RCTs were identified: ACTIVATION, NOTION-3, and PRO-TAVI, enrolling a total of 1,156 patients (579 PCI, 577 no-PCI).
• Statistical Analysis: Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models (DerSimonian–Laird estimator) to account for varying follow-up durations. Heterogeneity was assessed using the I² statistic. Sensitivity analyses (leave-one-out) were performed to test robustness.
• Outcomes: The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular death, myocardial infarction (MI), stroke, bleeding (any and major), revascularization (any and urgent), acute kidney injury (AKI), and rehospitalization.

Key Results

• Mortality: Routine PCI before TAVR did not significantly reduce all-cause mortality (HR 0.88, 95% CI 0.67–1.17; p=0.38) or cardiovascular death (HR 0.77, 95% CI 0.49–1.19; p=0.23). There was no heterogeneity (I² = 0%) for all-cause mortality.
• Revascularization: PCI significantly reduced the risk of subsequent any revascularization (HR 0.24, 95% CI 0.06–0.86; p=0.029) and urgent revascularization (HR 0.33, 95% CI 0.12–0.87; p=0.025). However, high heterogeneity (I² = 81.7%) was observed for any revascularization.
• Myocardial Infarction & Stroke: MI was not significantly reduced (HR 0.84, 95% CI 0.44–1.59; p=0.59). Stroke showed a borderline trend favoring PCI (HR 0.69, 95% CI 0.46–1.04; p=0.073) with no heterogeneity.
• Bleeding: PCI significantly increased the risk of any bleeding (HR 1.96, 95% CI 1.28–3.00; p=0.002) and major bleeding (HR 1.88, 95% CI 1.07–3.31; p=0.027). This finding was consistent across all trials.
• Other Outcomes: No significant differences were found for AKI (HR 1.20, 95% CI 0.31–4.64; p=0.788) or rehospitalization (HR 1.06, 95% CI 0.82–1.36; p=0.678).

Significance and Conclusions
The paper concludes that routine PCI before TAVR does not confer a mortality benefit in patients with severe AS and concomitant CAD. While the procedure effectively reduces the need for future urgent revascularization and may trend toward reducing stroke, these potential ischemic benefits are counterbalanced by a nearly two-fold increase in bleeding events.

The authors argue that these findings support a selective, individualized approach to revascularization rather than a routine strategy. Decisions should be guided by coronary anatomy, physiologic significance of lesions (e.g., FFR-guided assessment), symptom burden, and the patient's specific bleeding risk and frailty status. The study highlights that the trade-off between ischemic protection and hemorrhagic risk is the central clinical consideration in this population.

Limitations
The authors acknowledge limitations including the small number of included trials (n=3), varying follow-up durations (1 vs. 2 years), open-label designs introducing potential bias, and the lack of power to detect modest mortality differences. Additionally, subgroup analyses by CAD severity were not feasible due to the unavailability of individual patient data.